Cell Therapy

The biotechnology landscape in 2026 continues to grapple with the perceived necessity of high-classification cleanrooms for the collection of allogeneic starting materials, despite substantial evidence to the contrary. For years, the industry has operated under a pervasive assumption that the air

The quest to understand how malignant cells detach from a primary tumor and successfully colonize distant organs has long remained one of the most formidable challenges in modern oncology. While traditional therapies often succeed in shrinking localized masses, the ability of certain cells to evade

The scientific community has long searched for a way to reverse the cellular decay associated with chronic organ failure, yet recent breakthroughs suggest that a medication originally designed to repair cardiac tissue may hold the key to regenerating damaged kidneys. This innovative therapeutic

The emergence of chimeric antigen receptor T-cell therapy has revolutionized the oncological landscape by providing a potent "living drug" that can hunt and destroy malignant cells, yet nearly half of all patients still experience clinical relapses that threaten the long-term viability of this

As a seasoned biopharma expert with a career rooted in the intricacies of research and development, Ivan Kairatov has navigated the complex intersection of biotechnology and clinical innovation for years. His perspective is shaped by a deep understanding of how technological shifts can redefine

Living with Type 1 diabetes has historically meant a lifetime of constant surveillance, where every meal and physical activity requires a calculated response to maintain a delicate biological balance. For nearly a century, the medical standard of care focused almost exclusively on external